Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals announced the launch of a generic form of Sandostatin LAR Depot. The medication is ...
| DelveInsight The dynamics of the acromegaly market are anticipated to change due to extensive R&D, the entry of novel therapies such as Debio 4126 (Debiopharm International SA), ALXN2420 ...
A personalized treatment protocol was more effective for management of acromegaly -- also known as gigantism -- than the usual trial-and-error approach, the ...
Stay ahead with the most recent pipeline outlook for Acromegaly. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Acromegaly Treatment Drugs The ...
SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced it will present two abstracts at the American Association of Clinical Endocrinology (AACE) ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Nearly all responders to a 26-week course of oral ...
SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY TM (paltusotine) ...
LONDON, Nov. 13, 2018 /PRNewswire/ -- This report offers an eight year forecast on the global Cushing's syndrome and Acromegaly Treatment market. The primary objective of the report is to offer ...
LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results